Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04544111
Title PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

differentiated thyroid gland carcinoma

Therapies

Dabrafenib + Spartalizumab

Spartalizumab + Trametinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST